摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-(1H-imidazol-2-yl)-4-(2-chloro-4-fluorophenyl)-6-methyl-1,4-dihydro-pyrimidin-5-carboxylate | 1006047-32-0

中文名称
——
中文别名
——
英文名称
ethyl 2-(1H-imidazol-2-yl)-4-(2-chloro-4-fluorophenyl)-6-methyl-1,4-dihydro-pyrimidin-5-carboxylate
英文别名
ethyl 4-(2-chloro-4-fluorophenyl)-2-(1H-imidazol-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate
ethyl 2-(1H-imidazol-2-yl)-4-(2-chloro-4-fluorophenyl)-6-methyl-1,4-dihydro-pyrimidin-5-carboxylate化学式
CAS
1006047-32-0
化学式
C17H16ClFN4O2
mdl
——
分子量
362.791
InChiKey
QUTWWNOYENDVRD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    79.4
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases
    申请人:Beijing Molecule Science and Technology Co., Ltd.
    公开号:US08168642B2
    公开(公告)日:2012-05-01
    The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.
    本发明涉及式(I)的化合物或其药学上可接受的盐或水合物,制备式(I)的化合物的方法,以及将式(I)的化合物或其药学上可接受的盐或水合物用作药物,特别是用作治疗和预防B型肝炎的药物。
  • DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES
    申请人:Beijing Molecule Science and Technology Co., Ltd.
    公开号:EP2039686B1
    公开(公告)日:2012-02-29
  • US8168642B2
    申请人:——
    公开号:US8168642B2
    公开(公告)日:2012-05-01
  • Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases
    申请人:Li Song
    公开号:US20100087448A1
    公开(公告)日:2010-04-08
    The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.
    本发明涉及一种式(I)的化合物或其药学上可接受的盐或水合物,制备该式(I)化合物的方法,以及将该式(I)的化合物或其药学上可接受的盐或水合物用作药物,特别是用作治疗和预防乙型肝炎的药物。
查看更多